GLPwatch

Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus.

ACS Appl Mater Interfaces · 2019

Last updated 2026-05-28

Researchers developed an injectable hydrogel system designed to slowly release the diabetes drug exendin-4 (Ex-4) over a long period. In tests, the system formed a gel at body temperature and released Ex-4 gradually, with the release lasting a similar duration to the hydrogel's stability. The system showed potential for long-term, consistent blood sugar control in type 2 diabetes.

AI summary of the abstract below.

JournalACS Appl Mater Interfaces, 2019
Citations29
Relative citation ratio1.42
NIH percentile63
Molecules
Conditions studied Type 2 Diabetes

Abstract

Daily treatment of diabetes to stabilize blood glucose level poses a challenge for patients with diabetes mellitus. Diabetes is a long-term metabolic disorder, and the treatment lasts for the rest of the patient's life after diagnosis. We presented a new injectable hydrogel depot system using exendin 4 (Ex-4) interactive and complex forming polymeric ionic-nano-particles for long-term antidiabetes treatment. Protamine-conjugated polymer (ProCP) was developed to form ionic-nano-complexes with Ex-4, as the amino-group-rich protamine and the negatively charged Ex-4 ( pI: 4.86) interact with each other due to their opposite electric charges in physiological conditions. Morphologically, the ProCP were nanoparticles in aqueous condition (10 wt % of ProCP in phosphate-buffered solution, <25 °C) and formed condensed ionic- and nano-complexes with Ex-4. The complexes formed a bulk hydrogel when exposed to body temperature. A slow release of the Ex-4/ProCP ionic-nano-complexes occurred from the hydrogel depot, followed by Ex-4 dissociation from the ionic-nano-complexes and hydrolysis of ProCP. Given that the Ex-4 release occurs after the complex releases from the hydrogel, the periods of Ex-4 release and hydrogel maintenance may be similar. The present system showed a considerably prolonged Ex-4 release. Additionally, it showed potential as a long-term effective and reproducible antidiabetes treatment.

Verbatim abstract via PubMed 30945843 ↗